Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-3724 monotherapy for relapsed or refractory diffuse large B-cell lymphoma
MOH_2020-01-07_007473Phase 2Not yet recruiting
- Sponsor
- Molecular Templates, Inc.
- Start
- Dec 2019
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT-3724 in diffuse large B-cell lymphoma (DLBCL), sponsored by Molecular Templates, Inc. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
MT-3724
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2020-01-07_007473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-01-07_007473.